Savara is a clinical stage biopharmaceutical company focused on rare respiratory diseases. Our lead program, molgramostim nebulizer solution, is an inhaled granulocyte-macrophage colony-stimulating factor (GM-CSF) in Phase 3 development for autoimmune pulmonary alveolar proteinosis (aPAP). Our management team has significant experience in rare respiratory diseases and pulmonary medicine, identifying unmet needs, and effectively advancing product candidates to approval and commercialization. More information can be found at www.savarapharma.com. More information on the Phase 3 IMPALA-2 clinical trial in aPAP can be found at www.impala2.com
Location: United States, Colorado
Employees: 11-50
Total raised: $88.4M
Founded date: 2007
Investors 6
| Date | Name | Website |
| - | Puget Soun... | pugetsound... |
| - | Hercules C... | htgc.com |
| - | 37 Venture... | 37ventures... |
| - | Keiretsu F... | keiretsufo... |
| - | Haas Portm... | haasportma... |
| - | Bain Capit... | baincapita... |
Funding Rounds 7
| Date | Series | Amount | Investors |
| 21.04.2022 | - | $26.5M | - |
| 01.03.2016 | Series C | $20M | - |
| 21.03.2013 | Series B | $7.4M | - |
| 18.07.2012 | - | $3M | Keiretsu F... |
| 12.06.2012 | Series B | $8.6M | - |
| - | Series B | $16M | - |
| - | Series B | $6.9M | - |
Mentions in press and media 26
| Date | Title | Description |
| 31.03.2025 | Savara: Loan & Security Agreement Signed For Up To $200 Million With Hercules Capital | Savara – a clinical-stage biopharmaceutical company focused on rare respiratory diseases – announced that it has entered into a loan and security agreement with Hercules Capital for up to $200 million. And access to the additional capital s... |
| 13.07.2023 | Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock | - |
| 01.07.2021 | Savara : Announces First Patient Dosed in Pivotal Phase 3 Autoimmune Pulmonary Alveolar Proteinosis | AUSTIN, Texas - Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, announced that the first patient has been dosed in the pivotal IMPALA-2 clinical trial. IMPALA-2 is a Phase 3 trial... |
| 15.03.2021 | Savara Announces Closing of $130 Million Public Offering Following Full Exercise of Underwriters’ Option | AUSTIN, Texas--(BUSINESS WIRE)--Mar 15, 2021-- Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today announced the closing of its previously announced underwritten public offering of 57,479,978 shares of its common stock, includ... |
| 09.01.2017 | Savara jumping to the NYSE in reverse merger with zombie biotech Mast | After raising $20 million and laying out plans for a Phase III pivotal trial of a reformulated antibiotic, Savara is getting the new year underway with a public listing, courtesy of a reverse merger with the zombie bio... |
| 01.09.2016 | Ten Life Science Startups to Watch in Austin | |
| 23.06.2016 | Savara Pharmaceuticals Buys Serendex Pharmaceuticals | Savara Pharmaceuticals, which creates drugs focused on rare respiratory diseases, announced it has acquired the assets of Serendex Pharmaceuticals. |
| 01.03.2016 | Savara raises $20M to push its inhaled antibiotic into Phase III | Austin, TX, biotech Savara Pharmaceuticals picked up $20 million in Series C cash as it moves toward Phase III with an inhaled antibiotic designed to combat infections in patients with cystic fibrosis. The capital, drawn from undisclosed bo... |
| 01.03.2016 | Savara Pharmaceuticals Closes $20M Series C Financing | Savara Pharmaceuticals, an Austin, TX-based specialty pharmaceutical company focusing on innovative drugs for the treatment of serious and life-threatening rare respiratory diseases, closed a $20m Series C financing round. The backers remai... |
| 01.03.2016 | Daily funding roundup - March 1, 2016 | YourMechanic raised $24M, Savara Pharmaceuticals closed $20M; Replay Technologies raised $13.5M YourMechanic, provider of on-demand auto repair, secured $24 million in new funding from SoftBank Capital, Lerer Hippeau Ventures, Data Point Ca... |
Show more